These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 12208748

  • 21. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts.
    Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR.
    Cancer Res; 1997 Oct 01; 57(19):4205-9. PubMed ID: 9331076
    [Abstract] [Full Text] [Related]

  • 22. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
    Gnant MF, Puhlmann M, Alexander HR, Bartlett DL.
    Cancer Res; 1999 Jul 15; 59(14):3396-403. PubMed ID: 10416601
    [Abstract] [Full Text] [Related]

  • 23. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
    Kong H, Huang ZH, Li Q, Yang LC, Yu JL, Li Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun 15; 28(6):907-10. PubMed ID: 18583225
    [Abstract] [Full Text] [Related]

  • 24. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
    Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, Zhao HY, Zhang Y, Guan ZZ, Zhang L.
    Cancer Gene Ther; 2009 Sep 15; 16(9):723-30. PubMed ID: 19363470
    [Abstract] [Full Text] [Related]

  • 25. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
    Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ.
    J Urol; 2000 Jun 15; 163(6):1747-50. PubMed ID: 10799174
    [Abstract] [Full Text] [Related]

  • 26. Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
    Manome Y, Watanabe M, Abe T, Tomita M, Watanabe S, Yokokawa Y, Takahashi Y, Ishii K, Kimura A, Murakami M, Nagata M, Shibata T, Nakamura M, Tanigawa N, Ohno T.
    Anticancer Res; 2001 Jun 15; 21(4A):2265-72. PubMed ID: 11724281
    [Abstract] [Full Text] [Related]

  • 27. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
    Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY.
    Cancer Res; 2002 Feb 01; 62(3):773-80. PubMed ID: 11830532
    [Abstract] [Full Text] [Related]

  • 28. Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
    Corban-Wilhelm H, Hull WE, Becker G, Bauder-Wüst U, Greulich D, Debus J.
    Gene Ther; 2002 Dec 01; 9(23):1564-75. PubMed ID: 12424609
    [Abstract] [Full Text] [Related]

  • 29. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.
    Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL.
    J Clin Oncol; 2005 Nov 01; 23(31):7927-35. PubMed ID: 16258092
    [Abstract] [Full Text] [Related]

  • 30. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
    Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC.
    Cancer Gene Ther; 1998 Nov 01; 5(2):74-82. PubMed ID: 9570298
    [Abstract] [Full Text] [Related]

  • 31. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.
    Loimas S, Toppinen MR, Visakorpi T, Jänne J, Wahlfors J.
    Cancer Gene Ther; 2001 Feb 01; 8(2):137-44. PubMed ID: 11263529
    [Abstract] [Full Text] [Related]

  • 32. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
    Wildner O, Hoffmann D, Jogler C, Uberla K.
    Cancer Gene Ther; 2003 Oct 01; 10(10):791-802. PubMed ID: 14502232
    [Abstract] [Full Text] [Related]

  • 33. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
    Mathis JM, Williams BJ, Sibley DA, Carroll JL, Li J, Odaka Y, Barlow S, Nathan CO, Li BD, DeBenedetti A.
    J Gene Med; 2006 Sep 01; 8(9):1105-20. PubMed ID: 16802401
    [Abstract] [Full Text] [Related]

  • 34. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
    Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK.
    Cancer Res; 2001 Jul 15; 61(14):5447-52. PubMed ID: 11454690
    [Abstract] [Full Text] [Related]

  • 35. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.
    Cao X, Ju DW, Tao Q, Wang J, Wan T, Wang BM, Zhang W, Hamada H.
    Gene Ther; 1998 Aug 15; 5(8):1130-6. PubMed ID: 10326037
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy.
    Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO.
    Clin Cancer Res; 1997 Nov 15; 3(11):2081-8. PubMed ID: 9815600
    [Abstract] [Full Text] [Related]

  • 38. Gene therapy for prostate cancer.
    Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC.
    Expert Rev Anticancer Ther; 2002 Jun 15; 2(3):309-21. PubMed ID: 12113054
    [Abstract] [Full Text] [Related]

  • 39. Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coli cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration.
    Koyama F, Sawada H, Fujii H, Hirao T, Ueno M, Hamada H, Nakano H.
    J Exp Clin Cancer Res; 2000 Mar 15; 19(1):75-80. PubMed ID: 10840940
    [Abstract] [Full Text] [Related]

  • 40. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
    Cunningham C, Nemunaitis J.
    Hum Gene Ther; 2001 Aug 10; 12(12):1594-6. PubMed ID: 11529249
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.